News

Ondansetron Quells Methotrexate-Induced Nausea


 

EXPERT OPINION FROM THE ANNUAL CONGRESS OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

LISBON – Getting an earful of complaints of nausea from your patients on oral methotrexate therapy?

Consider bracketing the antifolate drug with the antiemetic ondansetron before and afterward, Dr. Richard B. Warren suggested at the congress.

Dr. Richard B. Warren

"One successful means of helping patients overcome their nausea that we’ve used a lot in Manchester is ondansetron. For some people it can literally sort out the nausea altogether," said Dr. Warren, senior lecturer and honorary consultant dermatologist at the University of Manchester (England).

The dosing is 8 mg of ondansetron (Zofran) – a serotonin receptor antagonist used to treat nausea caused by chemotherapy, radiation therapy, and/or surgery – administered 2 hours before and once again 12 hours after taking methotrexate.

Nausea is a common nuisance side effect of the drug. It affects roughly one-quarter of patients, typically beginning about 12 hours after they take their weekly dose. The nausea can last for up to 72 hours.

In addition to prophylactic ondansetron, other strategies that may be effective in overcoming methotrexate-induced nausea include the following:

– Divide the dose.

– Have patients take their oral methotrexate with the evening meal.

– Consider switching to subcutaneous methotrexate. "It has been shown to be more efficacious, and with less in the way of adverse events than oral methotrexate," Dr. Warren said.

He declared having no relevant financial interests.

Recommended Reading

Most Recreational Sports Do Not Elevate Osteoarthritis Risk
MDedge Internal Medicine
Accelerating Fracture Healing With Teriparatide
MDedge Internal Medicine
Vardenafil Increased Blood Flow in Raynaud Syndrome
MDedge Internal Medicine
B Cells Key in Takayasu Arteritis
MDedge Internal Medicine
Antiphospholipid Syndrome Plus Miscarriage Ups Clot Risk
MDedge Internal Medicine
Metabolic Syndrome Strikes Hard in Psoriatic Patients
MDedge Internal Medicine
RA, Periodontal Disease May Be Bi-Directional
MDedge Internal Medicine
FDA Advises Caution When IV Methotrexate-PPI Used Together
MDedge Internal Medicine
Don't Get Thrown for a Loop by Lyme Disease
MDedge Internal Medicine
Preview: Tofacitinib for Moderate to Severe RA
MDedge Internal Medicine